© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
Factors Affecting Patient Outcomes in Cancer Clinical Trials Tops SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
5. Ilixadencel/Sunitinib Combo Therapy Achieves Positive Results in Metastatic Renal Cell Cancer
Results from a phase 2 study demonstrated complete tumor responses in patients with metastatic renal cell carcinoma treated with the combination lixadencel and sunitinib. Read more.
4. Raising Levels of High-Density Lipoprotein May Reduce MS-Related Fatigue
Dietary interventions that raise levels of high-density lipoprotein, or good cholesterol, may affect fatigue symptoms in multiple sclerosis. Read more.
3. Two-Pronged Approach Shows Promise as Effective Treatment Option in AML
A new study identified pathways that may serve as therapeutic targets for overcoming drug resistance in acute myeloid leukemia. Read more.
2. FDA Accepts sNDA for Neratinib Use in HER2-Positive Metastatic Breast Cancer
Puma’s supplemental New Drug Application is seeking approval for the use neratinib (Nerlynx) plus capecitabine as a third-line treatment in patients with human epidermal growth receptor 2-positive metastatic breast cancer. Read more.
1. Socioeconomic, Insurance Status Can Affect Patient Benefit from Clinical Cancer Trials
Two studies examined whether health insurance and socioeconomic status played a role in patient outcomes in clinical cancer trials. Read more.